Peptide Protocol IQ
Not approved for human useHuman evidence

Selank

Also referred to as Tuftsin analogue, TP-7

An anxiolytic candidate with short trials in its originating jurisdiction and limited independent replication.

Molecule class
Synthetic heptapeptide tuftsin analogue
Category
Neurologic
Last evidence review
2026-08-23
Compare this compoundCheck interactionsSolution calculator
2
Human studies
0
Animal / in vitro
1
Graded claims
62
Participants

Mechanism

What is being studied

Proposed effects on GABAergic and monoaminergic signalling and on enkephalin degradation.

Evidence

Claims, graded individually

Each statement below carries its own evidence level, its own confidence rating, and its own account of what remains unestablished. A compound does not have a single grade.

Cognitive & Neurologic Research

CPreliminaryVery low confidenceHuman evidence

Selank has been reported in short trials in its originating jurisdiction to reduce anxiety ratings.

What is not established

Short duration, single jurisdiction, limited replication.

Supporting sources (2)
Randomised controlled trialHuman Identifier verified

Selank in the treatment of generalised anxiety disorder and neurasthenia

Zozulia AA, Neznamov GG, Siuniakov TS, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008 · n = 62

Population
Adults with generalised anxiety disorder or neurasthenia
Endpoint
Anxiety rating scales against a medazepam comparator
Route
Intranasal
Quantity as reported
Not stated. The published abstract reports no amount, concentration, route detail or frequency.
Frequency
Not stated

Result. Anxiolytic effect reported as comparable to the benzodiazepine comparator.

Adverse events. Limited systematic reporting.

Limitations. The identifier is real and the trial exists. The quantity does not appear in the published record at all, so there is no study arm on this site to attribute a Selank figure to.

PMID18454096
Randomised controlled trialHumanNo verified identifier on file

Selank in anxiety and cognitive research

Multiple · Predominantly Russian-language psychiatry literature · 2008

Population
Adults with generalised anxiety in the originating programme
Endpoint
Anxiety rating scales
Route
Intranasal
Quantity as reported
Intranasal formulation as registered in the originating jurisdiction
Frequency
Daily
Duration
2 weeks

Result. The originating literature reports anxiolytic effect comparable to a benzodiazepine comparator.

Adverse events. Limited systematic reporting.

Limitations. Single-jurisdiction evidence base, limited independent replication, short duration.

Search PubMed for this literature →

Last evidence review: 2026-08-23

Human evidence

2 human studies catalogued

Human and non-human evidence are kept strictly separate. They are never pooled, averaged, or presented as a single body of support.

Randomised controlled trialHumanNo verified identifier on file

Selank in anxiety and cognitive research

Multiple · Predominantly Russian-language psychiatry literature · 2008

Population
Adults with generalised anxiety in the originating programme
Endpoint
Anxiety rating scales
Route
Intranasal
Quantity as reported
Intranasal formulation as registered in the originating jurisdiction
Frequency
Daily
Duration
2 weeks

Result. The originating literature reports anxiolytic effect comparable to a benzodiazepine comparator.

Adverse events. Limited systematic reporting.

Limitations. Single-jurisdiction evidence base, limited independent replication, short duration.

Search PubMed for this literature →
Randomised controlled trialHuman Identifier verified

Selank in the treatment of generalised anxiety disorder and neurasthenia

Zozulia AA, Neznamov GG, Siuniakov TS, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008 · n = 62

Population
Adults with generalised anxiety disorder or neurasthenia
Endpoint
Anxiety rating scales against a medazepam comparator
Route
Intranasal
Quantity as reported
Not stated. The published abstract reports no amount, concentration, route detail or frequency.
Frequency
Not stated

Result. Anxiolytic effect reported as comparable to the benzodiazepine comparator.

Adverse events. Limited systematic reporting.

Limitations. The identifier is real and the trial exists. The quantity does not appear in the published record at all, so there is no study arm on this site to attribute a Selank figure to.

PMID18454096

Pharmacology

Reported parameters

Half-life

Not characterised

Not adequately characterised in accessible literature.

Routes studied

  • Intranasal

Evidence from one route does not transfer to another. Topical, oral, and injected administration can produce entirely different exposure from the same quantity.

Regulatory status

Not approved in the United States.

Storage as documented

No approved US labelling exists.

Safety

Signals reported in the literature

This lists what has been reported. It is not a complete safety profile, and for several compounds in this catalogue no systematic safety surveillance exists at all.

  • Limited systematic adverse-event reporting

Limitations

What the evidence cannot tell you

Given as much prominence as the findings, because for most compounds in this category it is the more important half.

  • Short trials, single jurisdiction, limited replication

Reference

Evidence grading key

AStrong

Multiple high-quality human trials, or strong systematic-review or meta-analytic evidence.

BModerate

Human controlled evidence exists, but replication or sample size is limited.

CPreliminary

Small human studies, observational evidence, or early-phase clinical work.

DPreclinical

Predominantly animal or in-vitro evidence. No adequate human outcome data.

EMechanistic

Biological plausibility or mechanistic reasoning without adequate outcome evidence.

XInsufficient / conflicting

Evidence is absent, irreconcilable, or too weak to support any directional statement.

Related

Other compounds studied in the same research areas

Semax

Registered as a medicine in its originating jurisdiction. The evidence base is concentrated there and has limited independent replication.